Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer
Abstract Recent trials have shown the efficacy of trastuzumab deruxtecan (T-DXd) in HER2-negative patients, but there is not yet a way to identify which patients will best respond, especially with the inability of current HER2 IHC and FISH assays to accurately determine HER2 expression in the unamplified setting.Here, we present a heavily pre-treat